MONDAY, July 8, 2019 (HealthDay News) -- The prevalence of infective endocarditis (IE) is about 26 percent among patients with Enterococcus faecalis bacteremia
, according to a study published in the July 16 issue of the Journal of the American College of Cardiology.
cereus causes severe nongastrointestinal infections, such as bacteremia
(2), endocarditis (3), meningoencephalitis (4), and pneumonia (5).
ContraFect announced that new data from its Phase 2 clinical trial of exebacase for the treatment of Staphylococcus aureus bacteremia
including endocarditis was presented by Vance Fowler, M.D., Professor of Medicine in the Division of Infectious Diseases, Duke University at a late-breaker session at the 29th European Congress of Clinical Microbiology and Infectious Diseases, or ECCMID.
in a case with late prosthesis infection and atypical complaints.
The prevalence of the complicated UTI including bacteremia
increases with age.1,2 The prevalence is high among elders with diabetes.
Infants with bacteremia
caused by group B streptococcus (GBS) who were treated with intravenous antimicrobial therapy for 8 days or less had similarly successful outcomes, compared with those treated longer, based on data from 775 infants.
In-hospital TB-related mortality rate was 19% (4/21) among MTBC-bacteremia patients and 4.8% (6/124) in those with no bacteremia
(p = 0.017) (Table 1).
Tigecycline is an alternative for MDR Acinetobacter baumannii and Klebsiella pneumoniae carbapenemase-producing bacteria (KPC), but it is not recommended for bacteremia
because it does not achieve adequate serum concentration levels and is associated to an increased risk of death (4-5).
Therefore, our study aimed to investigate the association of bacteremia
with in-hospital mortality and the risk factors for bacteremia
in cirrhotic patients with UGIB to assist decision-making for preventing complications, such as pneumonia and other infections, and treatment strategies of antibiotics use in the emergency department (ED).
was defined as at least one A .
Many different risk factors contributing to candidemia and bacteremia
have been reported in several studies (3-10).
Despite colistin and tigecycline as the last resorts, the optimal therapeutic regimen of CRAB bacteremia
has not been established, and the unavailability of new antibiotic pipeline in developing countries definitely restricts clinical therapeutic options and facilitates its dissemination.